Home

Aurobindo Pharma Ltd EPS

Image

Aurobindo Pharma Ltd

NSE: AUROPHARMA

EPS

₹ 60.7

Last updated on: Feb 21, 2025

Key Highlights

  • The Earning per Share of Aurobindo Pharma Ltd is ₹ 60.7 as of 21 Feb 25 .
  • The earning per share of Aurobindo Pharma Ltd changed from ₹ 9.74 to ₹ 14.56 over 7 quarters. This represents a CAGR of 25.83% .

Historical Earning per Share of Aurobindo Pharma Ltd

No data available

* All values are in

Company Fundamentals for Aurobindo Pharma Ltd

Market Cap

65,358 Cr

EPS

60.7

P/E Ratio (TTM)

18.4

P/B Ratio (TTM)

2.1

Day’s High

1125.55

Day’s Low

1097.75

DTE

0.3

ROE

11.6

52 Week High

1592.55

52 Week Low

985.0

ROCE

13.7

Market Price of Aurobindo Pharma Ltd

1M

1Y

3Y

5Y

Monitoring Aurobindo Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
21 Feb 20251115.45
20 Feb 20251120.85
19 Feb 20251136.3
18 Feb 20251164.05
17 Feb 20251170.05
14 Feb 20251129.8
13 Feb 20251180.05
12 Feb 20251145.2
11 Feb 20251146.8
10 Feb 20251176.8

SWOT Analysis Of Aurobindo Pharma Ltd

Strength

3

che

Weakness

2

che

Opportunity

0

che

Threats

1

che

BlinkX Score for Aurobindo Pharma Ltd

Asset Value vs Market Value of Aurobindo Pharma Ltd

Market Value

65,359

Asset Value

Value addition

1.6 X

25,059

* All values are in ₹ crores

Competitive Comparison of EPS

Company
leftMarket Capright
Aurobindo Pharma Ltd65358
Sun Pharmaceuticals Industries Ltd394223
Divis Laboratories Ltd152610
Cipla Ltd119067
Torrent Pharmaceuticals Ltd102739
Dr Reddys Laboratories Ltd96124

Historical Market Cap of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical Revenue of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical EBITDA of Aurobindo Pharma Ltd

No data available

* All values are in crore

Historical Net Profit of Aurobindo Pharma Ltd

No data available

* All values are in crore

Dividend Payout Over Time

No data available

Aurobindo Pharma Ltd News Hub

Aurobindo Pharma tumbles after US FDA issues warning letter to Telangana unit

In May 2024, the United States Food and Drug Administration (US FDA) had conducted an inspection at

Read more

16 Aug 24

Eugia Pharma Specialities receives USFDA warning for Unit III

Aurobindo Pharma announced that the USFDA has issued a warning letter for Unit-III of Eugia Pharma S

Read more

16 Aug 24

Aurobindo Pharma consolidated net profit rises 61.05% in the June 2024 quarter

Net profit of Aurobindo Pharma rose 61.05% to Rs 919.22 crore in the quarter ended June 2024 as agai

Read more

12 Aug 24

Auro Pharma Q3 PAT slides 10% YoY to Rs 846 crore

However, revenue from operations increased 8.53% year on year (YoY) to Rs 7,978.52 crore in the quar

Read more

07 Feb 25

Document

Annual Reports

Annual Report 2024

dropdown
download

Credit Ratings

Credit Report 2024

dropdown
download

Concalls

FAQs for EPS of Aurobindo Pharma Ltd

What is the EPS of Aurobindo Pharma Ltd stock?

The Earnings Per Share (EPS) of Aurobindo Pharma Ltd is 60.7. An EPS is the amount of net income attributed to each share of a common stock.

How is Aurobindo Pharma Ltd EPS calculated?

The EPS of Aurobindo Pharma Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Aurobindo Pharma Ltd report its EPS?

Aurobindo Pharma Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Aurobindo Pharma Ltd EPS?

Factors that influence the EPS of Aurobindo Pharma Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Aurobindo Pharma Ltd EPS growth indicate future performance?

Yes, consistent growth in Aurobindo Pharma Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions